Apart from the blockade of PD-1 receptors on T lymphocytes, the disruption of PD-1 immune checkpoint pathway by targeting of PD-L1 has also proven to be a promising approach for improving the effector activity of anti-tumor T cells. The gene discussed is PDCD1; the disease is neoplasm.